The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.Published in:Science Signaling, 2022, v. 15, n. 749, p. 1, doi. 10.1126/scisignal.abn2707By:Kurimchak, Alison M.;Herrera-Montávez, Carlos;Montserrat-Sangrà, Sara;Araiza-Olivera, Daniela;Hu, Jianping;Neumann-Domer, Ryan;Kuruvilla, Mathew;Bellacosa, Alfonso;Testa, Joseph R.;Jin, Jian;Duncan, James S.Publication type:Article